FDA: Majority of drug and biological product makers meeting postmarketing requirements and commitments
Most makers of approved drug and biological products are meeting their regulatory obligations and meeting targets for postmarketing studies/clinical trials in a timely manner, according to a study released today by the U.S. Food and Drug Administration (FDA).